Windows 10: the blocking for the 2004 version is lifted on the Surface

Technology: Microsoft was preventing certain Surface devices from updating to the 2004 version due to technical issues. The blockade was lifted on June 29.
Microsoft releases the block it placed on certain Surface devices to prevent them from updating to version 2004. This block prevented users of certain Surface models manufactured by Microsoft, including Surface Laptop 3 and Surface Pro 7, from downloading and manually install the latest Windows 10 feature update.

According to information released as part of the May 2020 update, devices with more than one network adapter capable of operating in "Always On, Always Connected" mode may experience unexpected shutdowns and reboots. The Surface Laptop 3 and Surface Pro 7 both fall into this category. (Other surface devices can also be included; I asked Microsoft for a list of affected devices, but got no response).

Several technical problems when launching the updateEven though a patch (KB4557957) was released on June 9 as part of …

France tightens access to chloroquine in pharmacies faced with the risk of shortage

In a press release published on Thursday, March 26 on its website, the National Agency for the Safety of Medicines and Health Products (ASNM) tells pharmacists the rules to follow regarding the delivery of hydroxychloroquine, recommended by certain infectiologists in the treatment coronavirus. An update that follows the decree framing the conditions of prescription of the drug.

France tightens access to chloroquine in pharmacies faced with the risk of shortage

Haro on hydroxychloroquine… Since Professor Didier Raoult, infectious disease specialist in Marseille, has presented it as the remedy for Covid-19, this molecule, marketed under the name of Plaquenil, has aroused an unusual craze. To the point that the Ministry of Health and the National Medicines Agency (ASNM) - which manages the famous marketing authorizations (AMM) - fear a shortage whose consequences would be dramatic for the tens of thousands of French people who treat their chronic pathologies (lupus, rheumatoid arthritis) with this drug.

To limit the danger, the Minister of Health Olivier VΓ©ran therefore issued a decree strictly governing the prescription of Plaquenil as well as another antiviral, Kaletra, also experienced in the treatment of coronavirus. Came into force on Thursday, the text provides that “the pharmaceutical specialty PLAQUENIL © and preparations based on hydroxychloroquine can only be dispensed by pharmacies as part of an initial prescription exclusively from specialists in rheumatology, internal medicine, dermatology, nephrology, neurology or pediatrics or as part of a refill from any doctor ”.

Under this text, only indoor pharmacies in healthcare establishments are now authorized to deliver Plaquenil "outside of marketing authorization", that is to say outside of its usual indications. What makes any prescription impossible for the liberal doctors, within the framework of the treatment of the coronavirus, for example.

On the other hand, the decree authorizes the prescription of Plaquenil outside MA, in the treatment of coronavirus, but it is reserved for hospital doctors: “Hydroxychloroquine and the combination lopinavir / ritonavir can be prescribed, dispensed and administered under the responsibility of a doctor to patients affected by Covid-19, in the health establishments which take charge of them, as well as, for the continuation of their treatment if their condition allows it and with the authorization of the initial prescriber, at home. ”

A few hours after the publication of the decree in the Official Journal, the National Medicines Agency has stepped up to clarify to city pharmacists the conditions for dispensing the drug. In a press release published on its website, the organization reports “difficulties in accessing city pharmacies to Plaquenil and Kaletra treatments for the chronically ill” and reminds pharmacists that to date neither Plaquenil nor Kaletra have no indication in the management of COVID-19 in the city. There is therefore no justification for their prescription in this indication ”. It remains to be seen whether this warning will be sufficient to avoid the shortage of hydroxychloroquine that threatens patients with chronic pathologies, particularly in the city of Lyon.